JP7134973B2 - Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 - Google Patents

Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 Download PDF

Info

Publication number
JP7134973B2
JP7134973B2 JP2019534721A JP2019534721A JP7134973B2 JP 7134973 B2 JP7134973 B2 JP 7134973B2 JP 2019534721 A JP2019534721 A JP 2019534721A JP 2019534721 A JP2019534721 A JP 2019534721A JP 7134973 B2 JP7134973 B2 JP 7134973B2
Authority
JP
Japan
Prior art keywords
pyrrolo
pyridin
pyridine
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019534721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502252A (ja
JP2020502252A5 (cg-RX-API-DMAC10.html
Inventor
ドレアス・アグニエシュカ
ファブリティウス・チャールズ－ヘンリー
ジニア・アンドレイ
ブダ・アンナ
ガレゾウスキ・ミカル
カシコフスキー・ゲオルギー
クレシャ・ウルシュラ
クバイ－ブライツ・カタジナ
サンボルスカ－グブル・アグニエシュカ
ツァーディボン・ウォイチェフ
ビレンチク・マリア
フリッド・マイケル
クズネツォワ・アレクサンドラ
Original Assignee
フェリシテックス・セラピューティクス，インコーポレイテッド
セルビタ エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリシテックス・セラピューティクス，インコーポレイテッド, セルビタ エス．エー． filed Critical フェリシテックス・セラピューティクス，インコーポレイテッド
Publication of JP2020502252A publication Critical patent/JP2020502252A/ja
Publication of JP2020502252A5 publication Critical patent/JP2020502252A5/ja
Priority to JP2022133200A priority Critical patent/JP2022166286A/ja
Application granted granted Critical
Publication of JP7134973B2 publication Critical patent/JP7134973B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019534721A 2016-12-23 2017-12-20 Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体 Expired - Fee Related JP7134973B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022133200A JP2022166286A (ja) 2016-12-23 2022-08-24 Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16460096 2016-12-23
EP16460096.7 2016-12-23
PCT/US2017/067527 WO2018119039A1 (en) 2016-12-23 2017-12-20 Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022133200A Division JP2022166286A (ja) 2016-12-23 2022-08-24 Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体

Publications (3)

Publication Number Publication Date
JP2020502252A JP2020502252A (ja) 2020-01-23
JP2020502252A5 JP2020502252A5 (cg-RX-API-DMAC10.html) 2021-01-28
JP7134973B2 true JP7134973B2 (ja) 2022-09-12

Family

ID=57777491

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534721A Expired - Fee Related JP7134973B2 (ja) 2016-12-23 2017-12-20 Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体
JP2022133200A Pending JP2022166286A (ja) 2016-12-23 2022-08-24 Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022133200A Pending JP2022166286A (ja) 2016-12-23 2022-08-24 Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体

Country Status (6)

Country Link
US (1) US10577365B2 (cg-RX-API-DMAC10.html)
EP (2) EP3558321B1 (cg-RX-API-DMAC10.html)
JP (2) JP7134973B2 (cg-RX-API-DMAC10.html)
LT (1) LT3558321T (cg-RX-API-DMAC10.html)
PL (1) PL3558321T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018119039A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022166286A (ja) * 2016-12-23 2022-11-01 フェリシテックス・セラピューティクス，インコーポレイテッド Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483508B (zh) * 2019-08-29 2020-05-08 山东大学 化合物、制备方法及在制备GSK-3β抑制剂中的应用
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
US11884647B2 (en) 2019-10-18 2024-01-30 The Regents Of The University Of California Compounds and methods for targeting pathogenic blood vessels
KR20230003981A (ko) * 2021-06-30 2023-01-06 한국화학연구원 DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도
WO2023064349A1 (en) * 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors
WO2023250082A2 (en) * 2022-06-22 2023-12-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
CN120904163B (zh) * 2025-10-09 2026-01-30 北京大学第一医院(北京大学第一临床医学院) 一种喹啉类化合物或其药学上可接受的盐及其制备方法和用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531760A (ja) 2004-03-30 2007-11-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2008523085A (ja) 2004-12-08 2008-07-03 スミスクライン・ビーチャム・コーポレイション １ｈ−ピロロ［２，３−ｂ］ピリジン
JP2009542684A (ja) 2006-06-30 2009-12-03 スネシス ファーマシューティカルズ ピリジノニルｐｄｋ１阻害剤
JP2012511000A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション ホスホイノシチド依存性キナーゼ１（ｐｄｋ１）の阻害剤
WO2012098068A1 (en) 2011-01-19 2012-07-26 F. Hoffmann-La Roche Ag Pyrazolo pyrimidines as dyrk1a and dyrk1b inhibitors
JP2013526609A (ja) 2010-05-24 2013-06-24 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
JP2013532727A (ja) 2010-07-30 2013-08-19 オンコセラピー・サイエンス株式会社 キノリン誘導体および同一物を含むｍｅｌｋ阻害剤
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
JP2014525928A (ja) 2011-08-19 2014-10-02 ディアクソンヒット Ｄｙｒｋ１阻害剤およびその使用
WO2016000615A1 (en) 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
WO2012129338A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
PL3141548T3 (pl) 2011-07-05 2020-09-07 Vertex Pharmaceuticals Incorporated Sposoby i związki pośrednie do wytwarzania azaindoli
PL3558321T3 (pl) * 2016-12-23 2023-10-23 Felicitex Therapeutics, Inc. Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531760A (ja) 2004-03-30 2007-11-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2008523085A (ja) 2004-12-08 2008-07-03 スミスクライン・ビーチャム・コーポレイション １ｈ−ピロロ［２，３−ｂ］ピリジン
JP2009542684A (ja) 2006-06-30 2009-12-03 スネシス ファーマシューティカルズ ピリジノニルｐｄｋ１阻害剤
JP2012511000A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション ホスホイノシチド依存性キナーゼ１（ｐｄｋ１）の阻害剤
JP2013526609A (ja) 2010-05-24 2013-06-24 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
JP2013532727A (ja) 2010-07-30 2013-08-19 オンコセラピー・サイエンス株式会社 キノリン誘導体および同一物を含むｍｅｌｋ阻害剤
WO2012098068A1 (en) 2011-01-19 2012-07-26 F. Hoffmann-La Roche Ag Pyrazolo pyrimidines as dyrk1a and dyrk1b inhibitors
JP2014525928A (ja) 2011-08-19 2014-10-02 ディアクソンヒット Ｄｙｒｋ１阻害剤およびその使用
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
WO2016000615A1 (en) 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022166286A (ja) * 2016-12-23 2022-11-01 フェリシテックス・セラピューティクス，インコーポレイテッド Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体

Also Published As

Publication number Publication date
US20180179199A1 (en) 2018-06-28
JP2020502252A (ja) 2020-01-23
JP2022166286A (ja) 2022-11-01
EP3558321A1 (en) 2019-10-30
WO2018119039A1 (en) 2018-06-28
US10577365B2 (en) 2020-03-03
LT3558321T (lt) 2023-05-10
EP4183786A1 (en) 2023-05-24
PL3558321T3 (pl) 2023-10-23
EP3558321A4 (en) 2020-05-27
EP3558321B1 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
JP2022166286A (ja) Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体
US11896592B2 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
US10947217B2 (en) Isoquinolin-3-YL carboxamides and preparation and use thereof
AU2017258187B2 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
CA2942997C (en) Heteroaryl syk inhibitors
AU2012303674B2 (en) Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
US20210393623A1 (en) Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
KR20180097749A (ko) Rock의 억제제로서의 스피로헵탄 살리실아미드 및 관련 화합물
WO2013085802A1 (en) Pyrrolopyrimidines as janus kinase inhibitors
AU2011306664A1 (en) Pyrazolopyridines as inhibitors of the kinase LRRK2
TW202404952A (zh) Qpctl及qpct之抑制劑
KR20160012194A (ko) 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
EP3652168A1 (en) 5-membered and bicyclic heterocyclic amides as inhibitors of rock
US20220220128A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CN115427409B (zh) 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物
HK40063823B (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
HK40091563A (en) Pyrimidinone compounds and uses thereof
NZ621436B2 (en) Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220831

R150 Certificate of patent or registration of utility model

Ref document number: 7134973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees